Iclusig (ponatinib) / Takeda, Otsuka 
Welcome,         Profile    Billing    Logout  
 56 Diseases   40 Trials   40 Trials   3062 News 
60 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iclusig (ponatinib) / Takeda, Otsuka
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie.

Not yet recruiting
4
198
Europe
Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso
Erasmus MC Cancer Institute, Erasmus MC
Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04]
 
 
2021-006581-20: A patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia

Not yet recruiting
4
106
Europe
Tablet, Capsule, hard, Imatinib, SPRYCEL, Bosulif, Tasigna, Iclusig
Radboud univeristy medical centre, ZonMw
Chronic myeloid leukaemia, Blood cancers, leukaemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-006048-15: The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and Blinatumomab, a specific monoclonal antibody, in adult patients, compared to the administration of chemotherapy and Imatinib. Lo studio ha lo scopo di verificare la maggiore efficacia del trattamento della Leucemia Linfoblastica Acuta Ph+ tramite la combinazione di Ponatinib e Blinatumomab, un anticorpo monoclonale specifico, in pazienti adulti, rispetto alla somministrazione di chemioterapia ed Imatinib.

Not yet recruiting
3
236
Europe
Iclusig, Blinatumomab, [NA], Film-coated tablet, Concentrate and solvent for solution for infusion, Iclusig 15 mg compresse rivestite con film, BLINCYTO - 38,5 MICROGRAMMI - POLVERE PER CONCENTRATO E SOLUZIONE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - POLVERE:FLACONCINO (VETRO) 38,5MCG - SOLUZIONE: 10 ML FLACONCINO (VETRO) - 1 FLACONCINO + 1 FLACONCINO
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Amgen S.r.l. via E. Tazzoli, 6 - 20154 - Milano, Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges, Switzerland
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Leucemia acuta linfoblastica Philadelphia-positiva dell'adulto., Acute lymphoblastic leukemia, a blood cancer that begins when the lymphocytes undergo neoplastic transformation in the marrow, with uncontrolled multiplication and progressive accumulation. Leucemia linfoblastica acuta, malattia tumorale del sangue che inizia quando i linfociti subiscono trasformazione neoplastica nel midollo, con moltiplicazione incontrollata e progressivo accumulo., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
GIMEMA, NCT04722848: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Recruiting
3
236
Europe
Ponatinib + Blinatumomab, Chemotherapy + Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
09/27
09/27
NCT04530565: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Recruiting
3
348
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Electrocardiography, ECG, EKG, Lumbar Puncture, LP, Spinal Tap, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
07/28
07/28
2018-003281-14: Study with ponatinib in patients with leukemia Estudio con ponatinib en pacientes con Leucemia

Not yet recruiting
2
80
Europe
PONATINIB, Film-coated tablet, ICLUSIG
Fundación CRIS contra el Cáncer, Incyte Biosciences International Sarl
Chronic myelogenous leukemia Leucemia Mieloide Crónica, Leukemia Leucemia, Diseases [C] - Cancer [C04]
 
 
2017-004674-34: OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS Etude de phase II évaluant la tolérance et l’efficacité de la combinaison du Ponatinib et de la 5-azacitidine dans les leucémies myeloïdes chroniques en phase d’accélération ou en transformation blastique myéloïde.

Not yet recruiting
2
40
Europe
Ponatinib, Capsule, PONATINIB
CENTRE HOSPITALIER DE VERSAILLES, INCYTE BIOSCIENCES France
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS leucémies myeloïdes chroniques en phase d’accélération ou en transformation blastique myéloïde, CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS leucémies myeloïdes chroniques en phase d’accélération ou en transformation blastique myéloïde, Diseases [C] - Cancer [C04]
 
 
2016-000618-30: Ponatinib for Treatment of Patients with CP-CML after treatment with other TKI has failed

Ongoing
2
54
Europe
Ponatinib, Tablet, Iclusig
GWT-TUD GmbH, Incyte Biosciences International S.à.r.l.
Adult patients (age ≥ 18) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) who have proven to be resistant or intolerant to prior first line Tyrosine Kinase Inhibitor Treatment, Adult patients (age ≥ 18) suffering from Chronic Myeloid Leukemia in Chronic Phase and who are resistant or intolerant to earlier treatment with another Tyrosine Kinase Inhibitor, Diseases [C] - Cancer [C04]
 
 
2018-001843-29: Trial to investigate if the addition of novel agents in combination with TKI can improve response compared to TKI alone in patients with TKI resistant chronic myeloid leukaemia.

Not yet recruiting
2
102
Europe
Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib, Tazemetostat, EPZ-6438, Film-coated tablet, Capsule, hard
NHS Greater Glasgow and Clyde, University of Glasgow, , Cancer Research UK, Epizyme
Chronic myeloid leukaemia, Chronic myeloid leukaemia, Diseases [C] - Cancer [C04]
 
 
2018-001789-41: Trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Essai évaluant la tolérance et l’efficacité d’un traitement d’induction par ponatinib suivi d’une phase de consolidation par imatinib chez des patients adultes atteints de leucémie myéloïde chronique en phase chronique (LMC PC)

Ongoing
2
170
Europe
ponatinib, Film-coated tablet, Iclusig
Centre Léon Bérard, Incyte Biosciences Distribution B.V
Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), all risk scores, ≤65 years Patients adultes atteints de leucémie myéloïde chronique en phase chronique (LMC PC), tous scores de risque et âgés ≤ 65 ans, CML-CP LMC PC, Diseases [C] - Cancer [C04]
 
 
2018-004564-59: WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSIONIN CHRONIC MYELOID LEUKEMIA

Not yet recruiting
2
60
Europe
Film-coated tablet, Iclusig
Heidelberg University, Incyte Biosciences International Sàrl
chronic myeloid leukemia in chronic phase, chronic myeloid leukemia in chronic phase, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
OPTIC, NCT02467270 / 2014-001617-12: Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Checkmark 3-year update of the OPTIC trial of Iclusig in patients with resistant chronic-phase chronic myeloid leukemia at ASH 2022
Nov 2022 - Nov 2022: 3-year update of the OPTIC trial of Iclusig in patients with resistant chronic-phase chronic myeloid leukemia at ASH 2022
Checkmark Data from OPTIC trial for chronic phase CML at ASCO 2021
May 2021 - May 2021: Data from OPTIC trial for chronic phase CML at ASCO 2021
Checkmark Data from OPTIC trial for chronic phase CML at SOHO 2020
More
Active, not recruiting
2
283
Europe, Canada, US, RoW
Ponatinib, Iclusig, AP24534
Takeda
Myeloid Leukemia, Chronic, Chronic Phase
04/20
12/24
PONALFIL, NCT02776605 / 2015-004202-41: Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

Active, not recruiting
2
30
Europe
Prednisone, Vincristine, Daunorubicin, Ponatinib, Mercaptopurine, Methotrexate, VP-16, ARA-C:, TIT, Autologous transplantation, Allo transplantation
PETHEMA Foundation
ALL
08/20
08/23
2020-003912-28: The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in patients: MRD positive (persistent or relapsed), patients after haematological and extra-haematological relapse and patients who do not have never achieved remission after any previous treatment. Lo scopo dello studio è quello di valutare l’efficacia del Ponatinib, in monoterapia o in combinazione con chemioterapia, nell’indurre una remissione in pazienti: MRD positivi (persistenti o recidivi), pazienti dopo ricaduta ematologica ed extra-ematologica e pazienti che non hanno mai raggiunto remissione dopo qualsiasi trattamento precedente.

Not yet recruiting
2
67
Europe
Iclusig, [NA], Film-coated tablet, Iclusig 15 mg compresse rivestite con film
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Incyte Biosciences International Sàrl, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Ph+ Acute Lymphoblastic Leukemia Leucemia Linfoblastica Acuta Ph+, Acute lymphoblastic leukemia is a blood cancer that originates from lymphocytes (white blood cells) and is characterized by an accumulation of these cells in the blood, bone marrow and other organs. La leucemia linfoblastica acuta è un tumore del sangue che origina dai linfociti (globuli bianchi) ed è caratterizzata da un accumulo di queste cellule nel sangue, nel midollo osseo e in altri organi., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02398825 / 2015-001102-34: Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

Active, not recruiting
2
16
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Chronic Phase, Adults
02/21
02/23
PonaZero, NCT04043676 / 2017-004565-27: Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Recruiting
2
40
Europe
Ponatinib
Fundación Teófilo Hernando, Spain
Chronic Myeloid Leukemia
04/22
04/23
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Active, not recruiting
2
90
RoW
Ponatinib, Iclusig, AP24534
Otsuka Beijing Research Institute
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
07/22
12/25
2022-000633-17: The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphia-negative ALL subtype, with a combination of the tyrosine kinase inhibitor ponatinib and chemotherapy. The main objective of the trial is to improve the percentace of patients that achieve a disease remission also at the molecular level. Lo studio ha lo scopo di trattare pazienti adulti affetti da LAL PH-Like, un sottotipo di LAL Philadephia-negativa, con un inibitore di tirosin chinasi, il ponatinib, in aggiunta alla chemioterapia. L'obiettivo è quello di migliorare la percentuale di pazienti che ottengono la remissione di malattia anche a livello molecolare.

Not yet recruiting
2
32
Europe
Iclusig, [NA], Film-coated tablet, Iclusig 15 mg compresse rivestite con film
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA
Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Leucemia acuta linfoblastica Philadelphia-negativa dell'adulto., Acute lymphoblastic leukemia, a blood cancer that begins when the lymphocytes undergo neoplastic transformation in the marrow, with uncontrolled multiplication and progressive accumulation. Leucemia linfoblastica acuta, malattia tumorale del sangue che inizia quando i linfociti subiscono trasformazione neoplastica nel midollo, con moltiplicazione incontrollata e progressivo accumulo., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04475731: Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

Active, not recruiting
2
67
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse
11/24
11/24
NCT02272998: Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Active, not recruiting
2
22
US
ponatinib hydrochloride, AP24534, Iclusig, multitargeted tyrosine kinase inhibitor AP24534, laboratory biomarker analysis
Sameek Roychowdhury
Malignant Neoplasm
11/22
11/23
PONALLO, NCT03690115: Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients

Active, not recruiting
2
24
Europe
Ponatinib 30 MG
Versailles Hospital
Leukemia, Myeloid, Acute
12/23
12/24
PONS, NCT03807479: Study in Patients With Chronic Leukemia

Terminated
2
18
Europe
Ponatinib, Iclusig
GWT-TUD GmbH, Incyte Biosciences International Sàrl
Leukemia, Myeloid, Chronic-Phase
02/23
08/23
2019-004491-19: A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia Eine multizentrische, einarmige Studie zur Bestimmung der Wirksamkeit, Sicherheit und Verträglichkeit des Tyrosinkinaseinhibitors Ponatinib bei erwachsenen Patienten mit minimaler Resterkrankung (MRD) einer Philadelphia-Chromosom-positiver akuter lymphatischen Leukämie

Not yet recruiting
2
20
Europe
Film-coated tablet, Iclusig®
Universitätsklinikum Frankfurt, Incyte Biosciences International Sàrl
minimal residual disease (MRD) in Philadelphia-Chromosome positiveacute lymphoblastic leukemia (Ph+ALL) minimale Resterkrankung (MRD) einer Philadelphia-Chromosompositivenakuten lymphatischen Leukämie, minimal residual disease (MRD) in Philadelphia-Chromosome positiveacute lymphoblastic leukemia (Ph+ALL) minimale Resterkrankung (MRD) einer Philadelphia-Chromosompositivenakuten lymphatischen Leukämie, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-000760-21: A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT versus TKI, blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab in suboptimal responders

Not yet recruiting
2
220
Europe
Blinatumomab, Imatinib, Rituximab, Methotrexate, PEGASPARAGASE, 6-Mercaptopurine, Cytarabine, Prednisolone, Vindesinesulfate, Cyclophosphamid, Film-coated tablet, Powder and solvent for concentrate for solution for infusion, , Iclusig ®, Blincyto
Goethe-University, Deutsches Zentrum für Luft- und Raumfahrt e. V. Fördernummer 01KG2121, AMGEN GmbH, Incyte Biosciences International
De novo Philadelphia-Chromosome positive acute lymphoblastic leukemia (Ph+ALL) De novo Philadelphia-Chromosom-positive akute lymphatische Leukämie, Newly diagnosed Philadelphia-Chromosome positive acute lymphoblastic leukemia Neu diagnostizierte Philadelphia Chromosom positive akute lymphatische Leukämie, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-004540-29: The effectivness and safety of ponatinib administered in combination with reduced chemotherapy in treatment of acute lymphoblastic leukemia in adults. Účinnost a bezpečnost ponatinibu podaného v kombinaci s redukovanou chemoterapií v léčbě akutní lymfoblastové leukémie dospělých

Not yet recruiting
2
32
RoW
cytarabine, cyclophosphamide, Dexamethasone, rituximab, vincristine, methotrexate, filgrastim, Film-coated tablet, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Injection, ICLUSIG 15 mg film-coated tablets
Ústav hematologie a krevní transfuze, Incyte Biosciences Distribution B.V., CZECRIN - Czech Clinical Research Infrastructure Network
NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA NOVĚ DIAGNOSTIKOVANÁ AKUTNÍ LYMFOBLASTOVÁ LEUKÉMIE S POZITIVITOU FILADELFSKÉHO CHROMOSOMU, Untreated Ph+ Acute Lymphoblastic Leukemia Neléčená Ph+ akutní lymfoblastová leukémie, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Recruiting
2
40
Europe
Ponatinib, Azacitidine
Versailles Hospital
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
12/23
12/24
EWALL-Ph-03, NCT04688983 / 2018-003350-25: Study in Adult Ph-positive ALL

Not yet recruiting
2
180
NA
Ponatinib, Blinatumomab, Blincyto, Imatinib
Cardiff University, , Cardiff university, Cardiff University
Acute Lymphoblastic Leukemia, Adult
01/24
01/26
NCI-2018-01186, NCT03147612: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients with Philadelphia Chromosome-Positive And/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Active, not recruiting
2
22
US
Blinatumomab, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Filgrastim, Filgrastim-aafi, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Ponatinib, AP-24534, AP24534, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Vincristine, Leurocristine, VCR, Vincrystine
M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia with BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
02/25
02/25
NCT04747912: Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Recruiting
2
25
US
Inotuzumab ozogamicin, Besponsa, Dasatinib, SPRYCEL, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexasone, Solurex®, and Baycadron®, Methotrexate, Otrexup™, Rasuvo®, Rheumatrex® and Trexall™. MTX, Amethopterin, and Methotrexate Sodium, Vincristine, Oncovin and Vincasar Pfs, Ponatinib, Iclusig, Methotrexate for Injection, Allogenic Stem Cell Transplantation
University of Chicago
Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
03/25
03/25
NCT04188405: Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Active, not recruiting
2
30
US
Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ponatinib, AP-24534, AP24534, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
09/25
09/25
Pona-CELL, NCT04554459: Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL

Terminated
2
4
RoW
Ponatinib 15 MG Oral Tablet, Iclusig, AP24534, L01XE24
Institute of Hematology and Blood Transfusion, Czech Republic, CZECRIN - Czech Clinical Research Infrastructure Network
Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed
09/23
07/24
CarPAs, NCT04709731 / 2018-001334-18: Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia

Not yet recruiting
2
50
Europe
Ponatinib 15mg QD, ICLUSIG, AP24534, Ponatinib 30mg QD
Associazione Italiana Pazienti Leucemia Mieloide Cronica
Chronic Myeloid Leukemia (CML)
10/24
04/25
NCI-2018-01078, NCT03263572: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Recruiting
2
90
US
Blinatumomab, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Ponatinib, AP-24534, AP24534
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Amgen, Takeda
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, t(9;22)
11/25
11/25
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
ResToP, NCT04160546: Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response

Active, not recruiting
2
80
Europe
Ponatinib 15 MG, Acetylsalicylic acid 100 MG
Fundacion CRIS de Investigación para Vencer el Cáncer, Incyte Biosciences UK, Apices Soluciones S.L.
Chronic Myeloid Leukemia, Chronic Phase
12/25
12/25
ASC4TARGET, NCT06514534: Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Not yet recruiting
2
20
NA
ABL001/Asciminib
Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML)
12/28
12/28
NCT05306301: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Recruiting
2
32
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chemotherapy, Leukemia, Acute Lymphoblastic
02/25
07/28
NCT01424982: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
2
88
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Doxorubicin, Adriablastin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Ponatinib, AP-24534, AP24534, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
10/25
10/25
NCT04845035: Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Withdrawn
2
23
US
Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy, Methotrexate and Cytarabine
University of Michigan Rogel Cancer Center, Takeda
Acute Lymphoblastic Leukemia
01/26
01/29
NCT05268003: A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Active, not recruiting
2
26
US
Ponatinib, Venetoclax, Mini-hyper CVD
M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Leukemia
10/26
10/26
TIPI, NCT04070443: Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Active, not recruiting
2
170
Europe
Ponatinib, Imatinib
Centre Leon Berard
Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia
06/29
06/29
GMALL-EVOLVE, NCT06061094: Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

Recruiting
2
220
Europe
Imatinib, Ponatinib, Blinatumomab, Indication for stem cell transplantation
Goethe University, Deutsche Leukämie- & Lymphom-Hilfe, German Federal Ministry of Education and Research
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
07/29
07/29
NCT01746836: Ponatinib Hydrochloride As Second Line Therapy in Treating Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recruiting
2
50
US
Laboratory Biomarker Analysis, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
12/30
12/30
NCT02428543: Ponatinib for FLT3-ITD Acute Myelogenous Leukemia

Active, not recruiting
1/2
49
Europe
Ponatinib and Cytarabine
Versailles Hospital
Acute Myeloid Lukemia
11/20
11/23
NCI-2018-01100, NCT03576547: Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Completed
1/2
11
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, t(9;22)
06/24
06/24
NCT06207123: A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Recruiting
1/2
15
US
LP-118, Ponatinib, Iclusig, Vincristine, Oncovin, Vincrex, Vincasar PES, Dexamethasone, DexPak, Decadron, Methotrexate, Otrexup, Xatmep, Rasuvo
University of Chicago
Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
12/26
12/26
INCB 84344-102, NCT03934372 / 2018-004878-99: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Recruiting
1/2
60
Europe
Ponatinib, Iclusig, INCB84344
Incyte Biosciences International Sàrl
Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Leukemia, Lymphoma, Solid Tumors
01/26
01/26
NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Completed
1/2
11
Europe, US, RoW
Ponatinib, Ponatinib AAF, Chemotherapy Agents
Takeda, Takeda Development Center Americas, Inc.
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
12/23
07/24
2012-005629-65: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose-finding study

Ongoing
1
15
Europe
Iclusig, Film-coated tablet, Iclusig
University of Birmingham, Bloodwise TAP, Ariad Pharmaceuticals
Chronic Myeloid Leukaemia (CML) in Blast Phase, CML is a cancer of the white blood cells which build up, disrupting the normal balance of cells in the blood and bone marrow. In Blast phase, the cancer invades the bone marrow and other organs., Diseases [C] - Cancer [C04]
 
 
ACTRN12614000810617: A phase Ib/II clinical evaluation of Ponatinib in combination with 5- Azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia (AMLM21)

Active, not recruiting
1
42
 
Australasian Leukaemia and Lymphoma Group, Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukaemia (FLT3-ITD positive)
 
 
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
NCT01549548: Compassionate Use Ponatinib

No Longer Available
N/A
US
Ponatinib, AP24534
OHSU Knight Cancer Institute, Ariad Pharmaceuticals
Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia
 
 
NCT03709017: Iclusig PMS in CML or Ph+ALL Patients

Active, not recruiting
N/A
50
RoW
Ponatinib, Iclusig
Korea Otsuka Pharmaceutical Co., Ltd.
Chronic Myeloid Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
11/22
06/23
NCT05743465: A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Completed
N/A
1769
US
No Intervention
Takeda
Leukemia
11/22
11/22
NCT04048564: Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

Completed
N/A
120
Europe
Incyte BioSciences France
Chronic Myeloid Leukemia
12/22
07/23
LALPh2022, NCT06175702: Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting
N/A
150
NA
Vincristine, Dexamethasone, Imatinib, Cytarabine, Mercaptopurine, Methotrexate, Ponatinib, allogeneic stem cell transplantation, Total body irradiation, Cyclophosphamide, Fludarabine
PETHEMA Foundation
Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL
12/28
12/30
PHOENICS, NCT06119269: Ponatinib in CML Patients in Chronic Phase

Recruiting
N/A
100
Europe
Therapeutic drug monitoring, Molecular Response
University of Pisa
Chronic Myeloid Leukemia, Chronic Phase
01/24
12/24
Ponderosa, NCT03933852: Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose

Active, not recruiting
N/A
100
Europe
University of Jena
Chronic Myeloid Leukemia, Chronic Phase
06/24
12/24
NCT06390306: The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Not yet recruiting
N/A
30
RoW
Ponatinib, Azacitidine, Venetoclax, Olverembatinib
Peking University People's Hospital, Wuhan Union Hospital, China, Henan Cancer Hospital, Zhejiang University, Peking Union Medical College, Nanfang Hospital, Southern Medical University, Beijing Chuiyangliu Hospital
Chronic Myeloid Leukemia
12/26
12/27

Download Options